Hypoglycemia and Medical Expenses in Patients with Type 2 Diabetes Mellitus: An Analysis Based on the Korea National Diabetes Program Cohort

Rhee, Sang Youl; Hong, Soo Min; Chon, Suk; Ahn, Kyu Jeung; Kim, Sung Hoon; Baik, Sei Hyun; Park, Yong Soo; Nam, Moon Suk; Lee, Kwan Woo; Woo, Jeong-Taek; Kim, Young Seol
February 2016
PLoS ONE;2/18/2016, Vol. 11 Issue 2, p1
Academic Journal
Background and Aims: Hypoglycemia is one of the most important adverse events in individuals with type 2 diabetes mellitus (T2DM). However, hypoglycemia-related events are usually overlooked and have been documented less in clinical practice. Materials and Methods: We evaluated the incidence, clinical characteristics, and medical expenses of hypoglycemia related events in T2DM patients based on the Korea National Diabetes Program (KNDP), which is the largest multi-center, prospective cohort in Korea (n = 4,350). For accurate outcomes, the KNDP data were merged with claims data from the Health Insurance Review and Assessment Service (HIRA) of Korea. Results: During a median follow-up period of 3.23 years (95% CI: 3.14, 3.19), 88 subjects (2.02%) were newly diagnosed with hypoglycemia, and the incidence of hypoglycemia was 6.44 cases per 1,000 person-years (PY). Individuals with hypoglycemia were significantly older (59.7±10.7 vs. 53.3±10.4 years, p < 0.001), had more hospital visits (121.94±126.88 days/PY, p < 0.001), had a longer hospital stays (16.13±29.21 days/PY, p < 0.001), and incurred greater medical costs ($2,447.56±4,056.38 vs. $1,336.37±3,403.39 /PY, p < 0.001) than subjects without hypoglycemia. Conclusion: Hypoglycemia-related events were infrequently identified among the medical records of T2DM subjects. However, they were associated significantly with poor clinical outcomes, and thus, hypoglycemia could have a substantial burden on the Korean national healthcare system.


Related Articles

  • Hypoglycaemia exacts extra costs in Canada.  // PharmacoEconomics & Outcomes News;7/24/2010, Issue 608, p7 

    The article discusses research on the association of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients in Canada, referencing a study by M. Bron and colleagues presented at the 70th Annual Scientific Sessions of the American Diabetes Association.

  • The Direct Medical Cost of Type 2 Diabetes. Brandle, Michael; Zhou, Honghong; Smith, Barbara R.K.; Marriott, Deanna; Burke, Ray; Tabaei, Bahman P.; Brown, Morton B.; Herman, William H. // Diabetes Care;Aug2003, Vol. 26 Issue 8, p2300 

    OBJECTIVE — To describe the direct medical costs associated with type 2 diabetes, as well as its treatments, complications, and comorbidities. RESEARCH DESIGN AND METHODS — We studied a random sample of 1,364 subjects with type 2 diabetes who were members of a Michigan health...

  • Type 2 Diabetes: Incremental Medical Care Costs During the First 8 Years After Diagnosis. Brown, Jonathan B.; Nichols, Gregory A.; Glauber, Harry S.; Bakst, Alan W. // Diabetes Care;Jul99, Vol. 22 Issue 7, p1116 

    Presents information on a study that described and analyzed the time course of medical care costs caused by type 2 diabetes, from the time of diagnosis through the first postdiagnostic years. Research design and methods; Results; Conclusions.

  • Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study. Seong, Jong-Mi; Choi, Nam-Kyong; Shin, Ju-Young; Chang, Yoosoo; Kim, Ye-Jee; Lee, Joongyub; Kim, Ju-Young; Park, Byung-Joo // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background/Objectives: Data on the comparative effectiveness of oral antidiabetics on cardiovascular outcomes in a clinical practice setting are limited. This study sought to determine whether a differential risk of cardiovascular disease (CVD) exists for the combination of a dipeptidyl...

  • Intensive blood glucose control for type 2 diabetes: meta-analysis.  // Africa Health;Mar2012, Vol. 34 Issue 3, p59 

    The article reports on a meta-analysis of intensive blood glucose control for type 2 diabetes, which found that intensive control could not minimize all-cause mortality, however, can increase the risk of severe hypoglycaemia by about 30%.

  • Exenatide more effective than insulinglargine in patients with type 2 diabetes.  // Australian Journal of Pharmacy;Feb2011, Vol. 92 Issue 1089, p71 

    The article presents a case study on the efficacy of exenatide on patients with type 2 diabetes. In the study, exenatide was compared with insulin gargine in adults with type 2 diabetes who had subtimum glycaemic control despite use of maximum tolerated doses of blood-glucose-lowering drugs for...

  • Antibacterials/insulin detemir/omeprazole interaction.  // Reactions Weekly;8/1/2013, Issue 1463, p9 

    The article presents a case study of an 82-year-old man with hypoglycaemia, which developed during treatment with amoxicillin, clarithromycin, omeprazole and insulin detemir for type 2 diabetes.

  • PEDIATRIC MANAGEMENT PROBLEMS. Belkengren, Richard; Sapala, Shirley // Pediatric Nursing;Mar/Apr2000, Vol. 26 Issue 2, p182 

    Presents the case of a 14-year-old female with Type I diabetes. Social and family history; Factors that contributed to the occurrence of hypoglycemia; Treatment for the disease.

  • Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes. Haak, Thomas // Clinical Medicine Insights: Endocrinology & Diabetes;2015, Issue 8, p1 

    Type 2 diabetes mellitus (T2DM) is a progressive condition requiring long-term treatment. Most patients with T2DM are unable to maintain normoglycemia using metformin alone; thus, combination therapy is a pivotal part of disease management. Addition of the dipeptidyl peptidase-4 inhibitor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics